Extracranial stereotactic radiotherapy in low and favourable intermediate risk prostate cancer

被引：0
|
作者：
Navarro Aznar, V. [1 ]
Mendez Villamon, A. [1 ]
Puertas Valino, M. D. M. [1 ]
Garcia Aguilera, C. [1 ]
Cerrolaza Pascual, M. [1 ]
Lanuza Pascual, A. [1 ]
Ponce Ortega, J. M. [1 ]
Colom, C. [1 ]
Garcia Gimeno, B. [1 ]
Tejedor Gutierrez, M. [1 ]
机构：
[1] Miguel Servet Hosp, Radiat Oncol, Zaragoza, Spain
来源：
RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1499
引用
收藏
页码：S1217 / S1218
页数：2
相关论文
共 50 条
  • [21] Comparative results of focal-cryoablation and stereotactic body radiotherapy in the treatment of unilateral, low-to-intermediate-risk prostate cancer
    Monaco, Ashley
    Sommer, Jessica
    Okpara, Chinyere
    Lischalk, Jonathan W.
    Haas, Jonathan
    Corcoran, Anthony
    Katz, Aaron
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2022, 54 (10) : 2529 - 2535
  • [22] SHARP hypofractionated stereotactic radiotherapy is low and intermediate-risk prostate carcinoma patients - PSA outcome
    Rucinska, M.
    Osowiecka, K.
    Nawrocki, S.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S193 - S194
  • [23] PATHOLOGICAL OUTCOMES IN FAVOURABLE VERSUS UNFAVOURABLE INTERMEDIATE RISK PROSTATE CANCER
    Napodano, Giorgio
    Realfonso, Tommaso
    Campitelli, Antonio
    Intilla, Olivier
    Molisso, Giovanni
    Addesso, Maria
    Baio, Raffaele
    Sanseverino, Roberto
    ANTICANCER RESEARCH, 2019, 39 (03) : 1539 - 1541
  • [24] Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy
    Tsang, Yat Man
    Tharmalingam, Hannah
    Belessiotis-Richards, Katherine
    Armstrong, Shreya
    Ostler, Peter
    Hughes, Robert
    Alonzi, Roberto
    Hoskin, Peter J.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : 184 - 190
  • [25] Genomic prostate score and treatment selection in favourable intermediate-risk prostate cancer
    Margolis, Eric
    Lowentritt, Benjamin H.
    Pieczonka, Christopher M.
    Bennett, John P.
    Pavlova, Marina
    Zambon, Joao Paulo
    Groskopf, Jack
    Uchio, Edward
    BJUI COMPASS, 2025, 6 (03):
  • [26] STEREOTACTIC RADIOTHERAPY WITH BEACON TRANSPONDERS IN INTERMEDIATE-RISK PROSTATE CANCER: PRELIMINARY RESULTS OF TOXICITY AND EFFICACY
    D'agostino, Giuseppe Roberto
    Di Brina, Lucia
    Franzese, Ciro
    Pasini, Luisa
    Benetti, Alessio
    Navarria, Pierina
    De Rose, Fiorenza
    Franceschini, Davide
    Mancosu, Pietro
    Scorsetti, Marta
    ANTICANCER RESEARCH, 2017, 37 (04) : 2096 - 2097
  • [27] Stereotactic radiotherapy for prostate cancer
    Quero, L.
    Hennequin, C.
    CANCER RADIOTHERAPIE, 2014, 18 (04): : 332 - 336
  • [28] Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
    Borzillo, Valentina
    Scipilliti, Esmeralda
    Pezzulla, Donato
    Serra, Marcello
    Ametrano, Gianluca
    Quarto, Giuseppe
    Perdona, Sisto
    Rossetti, Sabrina
    Pignata, Sandro
    Crispo, Anna
    Di Gennaro, Piergiacomo
    D'Alesio, Valentina
    Arrichiello, Cecilia
    Buonanno, Francesca
    Mercogliano, Simona
    Russo, Antonio
    Tufano, Antonio
    Di Franco, Rossella
    Muto, Paolo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Hormone therapy and radiotherapy for intermediate risk prostate cancer
    Lee, Irwin
    Sandler, Howard
    SEMINARS IN RADIATION ONCOLOGY, 2008, 18 (01) : 7 - 14
  • [30] Clinical outcomes of whole pelvis radiotherapy and stereotactic body radiotherapy boost for intermediate- and high-risk prostate cancer
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E342 - E347
12345